Literature DB >> 23020725

Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.

Geoffrey R Oxnard1.   

Abstract

Acquired resistance to targeted therapy in epidermal growth factor receptor (EGFR)-mutant lung cancer represents a valuable model for considering strategies of overcoming different types of cellular resistance mechanisms. Using existing data on resistance in EGFR-mutant lung cancer, this review will discuss 3 basic approaches for overcoming resistance to EGFR-targeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and changing to anticancer therapies acting via alternate pathways.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23020725     DOI： 10.5858/arpa.2012-0254-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN： 0003-9985            Impact factor:   5.534


  9 in total

1.  Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors.

Authors:  Geoffrey R Oxnard; Katharine H Wilcox; Mithat Gonen; Mikhael Polotsky; Bradford R Hirsch; Lawrence H Schwartz
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

2.  Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

Authors:  Fei-fei Teng; Jian-dong Zhang; Xue Meng; Jin-ming Yu
Journal:  Cancer Biol Ther       Date:  2013-12-06       Impact factor: 4.742

3.  Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex.

Authors:  Paola D Vermeer; Paul L Colbert; Bryant G Wieking; Daniel W Vermeer; John H Lee
Journal:  Cancer Res       Date:  2013-06-28       Impact factor: 12.701

4.  Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer.

Authors:  Zhengbo Song; Yiping Zhang
Journal:  Arch Med Sci       Date:  2016-02-02       Impact factor: 3.318

5.  Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer.

Authors:  Xiaodong Mu; Ye Zhang; Xiujuan Qu; Kezuo Hou; Jian Kang; Xuejun Hu; Yunpeng Liu
Journal:  Biomed Res Int       Date:  2013-03-19       Impact factor: 3.411

6.  Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.

Authors:  Song Yi Bae; Ji-Young Hong; Hye-Jung Lee; Hyen Joo Park; Sang Kook Lee
Journal:  Oncotarget       Date:  2015-04-30

Review 7.  The distinctive nature of adenocarcinoma of the lung.

Authors:  Giandomenico Roviello
Journal:  Onco Targets Ther       Date:  2015-09-02       Impact factor: 4.147

8.  Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways.

Authors:  M V Bais; G B Ozdener; G E Sonenshein; P C Trackman
Journal:  Oncogene       Date:  2014-06-02       Impact factor: 9.867

Review 9.  Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.

Authors:  A Quintanal-Villalonga; Luis Paz-Ares; Irene Ferrer; S Molina-Pinelo
Journal:  Dis Markers       Date:  2016-07-26       Impact factor: 3.434
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.